Professor Christopher Goldring BSc, PhD
Lecturer Pharmacology & Therapeutics
- +44 (0)151 794 5979
- Work email C.E.P.Goldring@liverpool.ac.uk
- About
- Research
- Publications
- Teaching
Research
Research Grants
Developing a collaborative resource for ChIP based analyses of cancer related transcriptional networks
CANCER RESEARCH UK (UK)
April 2012 - March 2013
Vacation Scholarship. The role of the Nrf2-keap 1 pathway in regulation of chemoresistance.
WELLCOME TRUST (UK)
July 2008 - August 2008
Regenerative Medicine Platform in Stem Cell Safety Science
MEDICAL RESEARCH COUNCIL
June 2013 - March 2018
Definition of the mechanisms that underlie the decrease in expression of the cytochrome P450s in primary hepatocytes.
BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL
June 2007 - December 2009
Manipulation of the physiological and toxicological phenotype of human hepatocytes by targeting cellular differentiation and de-differentiation
MEDICAL RESEARCH COUNCIL
October 2014 - September 2018
Investigation of Inflammatory Signalling during Drug-induced Hepatotoxicity Background
BRITISH TOXICOLOGY SOCIETY (UK)
October 2007 - September 2010
The chemical and molecular basis of the prevention of drug-induced liver injury by Nrf2.
WELLCOME TRUST (UK)
January 2007 - December 2009
Pharmacogenetic and functional analysis of novel GSTP1 polymorphism.
ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)
May 2005 - January 2007
Investigation of the role of Nrf2 in man
WELLCOME TRUST (UK)
October 2011 - May 2015
Mechanism and effect of Chinese antioxidant herbs on phase II drug-metabolizing enzymes.
ROYAL SOCIETY (CHARITABLE)
July 2005 - October 2005
Capacity building award in integrative mammalian biology
BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL
January 2007 - October 2015
Biomedical Vacation Scholarships
WELLCOME TRUST (UK)
July 2010 - August 2010
University of Liverpool Institutional Discipline Bridging.
MEDICAL RESEARCH COUNCIL
October 2003 - October 2006
Analysis of inter-individual variation in the inducibility of the antioxidant response by Nrf2: an important element in the defence against cancer.
NORTH WEST CANCER RESEARCH FUND
May 2005 - April 2006
Hepatocyte Phenotype Project: Phase II proposal
STEM CELLS FOR SAFER MEDICINES LTD (UK)
May 2011 - May 2014